Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Insulin Lispro (Humalog) vs PT-141 (Bremelanotide)
An educational, source-based comparison of Insulin Lispro (Humalog) and PT-141 (Bremelanotide) — how each peptide works, what it's researched for, and what to know before going deeper.
Recombinant insulin analog with reversed lysine and proline at B28/B29, reducing self-association so it acts within ~15 minutes for postprandial glucose control.
- Prandial coverage in T1D/T2D
- Insulin pump therapy
- Hyperglycemic crises (with caution)
- • FDA-approved.
- • Hypoglycemia risk if meal delayed or skipped.
Melanocortin agonist researched for sexual desire and arousal.
A synthetic analog of α-MSH that activates melanocortin receptors (primarily MC4R) in the central nervous system. Unlike PDE5 inhibitors, it acts on neural pathways governing sexual desire rather than vascular flow.
- Hypoactive sexual desire disorder (FDA-approved as Vyleesi in premenopausal women)
- Male erectile response (research)
- Central arousal pathways
- • FDA-approved (Vyleesi) only for HSDD in premenopausal women.
- • Can cause nausea, flushing, transient blood pressure increases.
- • Avoid in uncontrolled hypertension or cardiovascular disease.
Insulin Lispro (Humalog) vs PT-141 (Bremelanotide) — Key differences
- Class: Insulin Lispro (Humalog) is classified as Insulin Analog · Endocrine, while PT-141 (Bremelanotide) is Sexual Health · Neurologic.
- Primary research focus: Insulin Lispro (Humalog) — prandial coverage in t1d/t2d; PT-141 (Bremelanotide) — hypoactive sexual desire disorder (fda-approved as vyleesi in premenopausal women).
- Tag: FDA-Approved · Diabetes vs Libido.